Pacira BioSciences (PCRX) FY2014 results: revenue $198 million, up 131.1% on the year
Pacira BioSciences, Inc. (PCRX) reported revenue of $198 million for fiscal 2014, the year ended 31 December 2014, up 131.1% on the year before. Net income was -$14 million, and diluted earnings per share $-0.39. The figures are the company's own, from the 10-K it filed with the SEC on 24 February 2015.
Revenue
$198 million
+131.1% on the year
FY2009FY2014
Operating margin
-2.6%
-62.3% a year earlier
FY2009FY2014
Net income
-$14 million
FY2009FY2014
Diluted EPS
-$0.39
FY2009FY2014
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Revenue
198
85.6
39.1
+131.1%
Cost of revenue
77.4
54.8
32.1
+41.4%
Gross profit
120
30.8
6.9
+290.6%
Gross margin
60.8%
36.0%
17.8%
Research and development
18.7
21.6
9.9
-13.1%
Selling, general and administrative
107
62.5
46.3
+70.6%
Operating income
-5.2
-53.3
-49.3
Operating margin
-2.6%
-62.3%
-126.1%
Interest expense
8.3
7.3
1.8
+14.1%
Pre-tax income
-13.5
-64.4
-52.3
Income tax
0.2
-0.4
0.0
Net income
-13.7
-63.9
-52.3
Net margin
-6.9%
-74.7%
-133.8%
Diluted EPS
-$0.39
-$1.93
-$1.72
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Operating cash flow
n/a
-43.8
-70.1
Capital expenditure
23.0
12.2
18.3
+88.8%
Free cash flow
n/a
-56.0
-88.4
Free cash flow margin
n/a
-65.5%
-226.1%
Depreciation and amortisation
10.0
5.7
5.6
+74.6%
Share-based compensation
24.8
11.5
4.8
+115.6%
Diluted shares, weighted
35m
33m
30m
+6.4%
Shares outstanding at period end
36m
34m
33m
+7.5%
Balance sheet
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Shareholders' equity
171
41.2
65.9
+314.9%
Debt
103
99.0
25.2
+4.2%
Other liabilities
51.8
29.6
21.0
+75.0%
Total liabilities and equity
326
170
112
+92.0%
Fixed assets
60.6
48.2
39.1
+25.8%
Goodwill
23.8
10.3
8.3
+130.1%
Intangible assets
0.4
1.2
3.2
-65.2%
Investments
144
59.6
30.9
+140.7%
Cash and equivalents
37.5
12.5
12.5
+199.8%
Receivables
22.4
14.6
4.4
+53.3%
Inventory
29.3
15.6
12.1
+88.1%
Other assets
8.6
7.9
1.6
+9.0%
Total assets
326
170
112
+92.0%
10-K for the year ended 31 December 2014, filed 24 February 2015: the filing.